Free Submission Public Relations & NewsPR-inside.com
 
DeutschEnglish

Get the latest news
with our RSS feed
rss feed
Add to My Yahoo!
More information
Miscellaneous
Sepracor Inc - PharmaVitae Profile

Sepracor Inc has achieved profitability following the launches of Xopenex HFA and Lunesta in 2005


Print article Print article
Refer this article Refer to a friend
© companiesandmarkets.com
2008-06-18 13:39:28 - www.companiesandmarkets.com adds new report - Sepracor Inc - PharmaVitae Profile

www.companiesandmarkets.com/Summary-General/Sepracor-Inc-PharmaV ..

Introduction

This analysis examines the historical and forecast performance for Sepracor in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

Benchmark Sepracor's performance against

key rivals in the ethical pharmaceutical sector
See how the company has achieved profitability following the launches of Xopenex HFA and Lunesta in 2005
Evaluate Sepracor's long-term growth prospects in the context of the expected 2010 patent expiry of its first product, Xopenex Inhalation Solution

www.companiesandmarkets.com/Summary-General/Sepracor-Inc-PharmaV ..


Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: 01933674780

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.


Terms & Conditions | About us | Contact PR-inside.com